This work was funded by National Institutes of Health National Institute on Drug Abuse [Grants UG3DA048387, UG3DA048387-S1, and R01DA048417] (to C.P.F.) and [Grant R01DA058018] (to T.H.) and by the Welch Foundation [Grant AQ-0039] (to C.P.F.). Funding sources were not involved beyond financial support of the present study. The content is solely the responsibility of the authors and does not necessarily represent the official views of National Institutes of Health or National Institute on Drug Abuse.

T.H. and N.P.H. have no conflicts to declare. C.P.F. is coholder of a US patent for methocinnamox.

Portions of these data were presented as follows:

1. Ho NP, Hiranita T, and France CP (2022) Effects of fentanyl alone and in combination with methamphetamine on ventilation and rectal temperature in rat. ACP Florida Chapter 2022 Meeting; 2022 Jul 27 (virtual presentation). American College of Physicians, Florida Chapter, Jacksonville, FL.

2. Ho NP, Hiranita T, and France CP (2022) Effects of fentanyl alone and in combination with methamphetamine on ventilation and rectal temperature in rat. ACP Florida Chapter 2022 Annual Scientific Meeting; 2022 Oct 21–23; Fort Lauderdale, FL. American College of Physicians, Florida Chapter, Jacksonville, FL.

3. Hiranita T, Ho NP, and France CP (2023) Comparison of the mu-opioid receptor antagonists methocinnamox (MCAM) and naloxone to reverse the ventilatory-depressant effects of fentanyl, heroin, and carfentanil in rats. 33rd Annual Scientific Meeting of the TRSA; 2023 Feb 17; Bryan, TX. Texas Research Society on Alcoholism, Austin, TX.

4. Hiranita T, Ho NP, and France CP (2023) Comparison of methocinnamox (MCAM) and naloxone to reverse and prevent the ventilatory depressant effects of fentanyl, heroin, and carfentanil in rats. 15th Annual BBC Meeting; 2023 Mar 25–26; San Antonio, TX. Behavior, Biology, and Chemistry Translational Research in Substance Use Disorders, San Antonio, TX.

5. Hiranita T, Ho NP, and France CP (2023) Comparison of the mu-opioid receptor antagonists methocinnamox (MCAM) and naloxone to reverse the ventilatory depressant effects of fentanyl, heroin, carfentanil, and 3-methylfentanyl in male rats. 20th Annual CBN Retreat; 2023 May 12; San Antonio, TX. Center for Biomedical Neuroscience, San Antonio, TX.

6. Hiranita T, Ho NP, and France CP (2023) Comparison of the mu-opioid receptor antagonists methocinnamox (MCAM) and naloxone to reverse the ventilatory-depressant effects of fentanyl and heroin in male rats. ASPET 2023 Annual Meeting; 2023 May 18–21; St. Louis, MO. Annual American Society for Pharmacology and Experimental Therapeutics, Rockville, MD.

7. Hiranita T, Ho NP, and France CP (2023) Ventilatory effects of fentanyl, heroin, and d-methamphetamine, alone and in mixtures, in male rats. CPDD 85th Annual Scientific Meeting; 2023 Jun 17–21; Denver, CO. College on Problems of Drug Dependence, Brentwood, TN.

dx.doi.org/10.1124/jpet.123.002032.

↵This article has supplemental material available at jpet.aspetjournals.org.